Alexei G. Basnakian

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Professor

UAMS primary Arkansas State University NCTR

Also affiliated: Boston Biomedical Research Institute (1989); Russian Academy of Sciences (1991); University of Debrecen (2005); University of Arkansas Medical Center (2005–2020); Ege University (2007); Central Arkansas Veterans Healthcare System (2001–2025); Winthrop Rockefeller Foundation (2022–2025); Institute of Biomedical Chemistry (1991); John L. McClellan Memorial Veterans Hospital (2009–2024); Arkansas Department of Agriculture (2013)

Faculty Researcher

36 h-index 142 pubs 4,095 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Alexei G. Basnakian's research program investigates mechanisms of cell death and injury, with a particular focus on DNA damage and its role in various biological processes. His work has explored the function of endonucleases, such as Endonuclease G, in promoting autophagy and suppressing mTOR signaling, as well as activating the DNA damage response. Basnakian has also examined the TUNEL assay as a tool for evaluating kidney injury.

His research extends to the study of therapeutic interventions for radiation-induced injuries and other conditions. This includes investigating the effects of gamma-tocotrienol on intestinal injury in nonhuman primate models of acute radiation syndrome. Basnakian's group has also explored the potential of oncolytic virotherapy for liver cancers and the development of novel antimicrobial agents and anti-melanoma compounds.

Basnakian leads a research group at the University of Arkansas for Medical Sciences and maintains an active lab website. He has a publication record of 142 papers, with an h-index of 36 and over 4,000 citations. He has collaborated extensively with researchers at his institution, including Martin J. Cannon, Steven R. Post, Camila Simões, and Mulu Z. Tesfay.

Metrics

h-index: 36
Publications: 142
Citations: 4,095

Selected Publications

Dual Targeting of EZH2 and LSD1 Suppresses Hepatocellular Carcinoma via Disruption of Sonic Hedgehog Signaling (2026)

International Journal of Molecular Sciences DOI OpenAlex
Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)

Cancer Research DOI OpenAlex
An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates (2026)

Journal of Biological Chemistry DOI OpenAlex
Design, Synthesis, and Development of 4-[2-[3,5-Bis(trifluoromethyl)anilino]thiazolo-4-yl]phenol as a Dual Inhibitor of Fatty Acid Biosynthesis (FASII) to Clear MRSA Infection (2026)

ChemRxiv 1 citation DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)

Journal for ImmunoTherapy of Cancer DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

Cancer Research DOI OpenAlex
An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates (2025)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

Cancer Research DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

Cancer Research DOI OpenAlex
Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2025)

RSC Medicinal Chemistry DOI OpenAlex
The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury (2025)

American Journal of Physiology-Renal Physiology 3 citations DOI OpenAlex
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)

RSC Medicinal Chemistry 1 citation DOI OpenAlex
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024)

Journal of Medicinal Chemistry 4 citations DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

Biomedicines 5 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 2

VA Contact PI Oct 2022 - Sep 2027

BLRD Research Career Scientist Award Application

Administered by Central Arkansas Veterans Healthcare System IK6

VA Contact PI Oct 2014 - Aug 2028

Nuclease mechanisms in acute kidney injury

Administered by Central Arkansas Veterans Healthcare System I01

Grants & Funding

As listed on this researcher's institutional profile. Federal awards with verified records are shown above.

The role of endonuclease G in nuclear apoptosis of atrophying skeletal muscle NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases via University of Kentucky Research Foundation
Endonuclease-targeted radioprotection NIH/Nat. Inst. of Allergy & Infectious Diseases via Duke University
Endonuclease dificiency in breast cancer progression NIH
Novel DNA damage-based technology for evaluation of graphene toxicity in vitro and in vivo U.S. Food and Drug Administration via Arkansas Research Alliance
A nanotherapeutic approach to combat staphylococcal biofilm-associated infection NIH
CRIC Ancillary Study: Carbamylated low-density lipoprotein and cardiovascular eve NIH
LDL isoforms in kidney-related atherosclerosisv NIH
Using Advanced Functional Nanomaterials to Fight Cancer. U.S. Army Medical Research & Materiel Command via University of Arkansas at Little Rock